Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY1105
- Development stage
- Preclinical
- Lead developer
- KYDES Pharmaceuticals
- Modality
- Small Molecules
01
Overview
KY1105 is a small molecule therapeutic candidate being developed by KYDES Pharmaceuticals for the treatment of persistent Human Papillomavirus (HPV) infection and cervical dysplasia. Currently in the preclinical stage of development, the drug is designed to address the viral persistence that leads to dysplastic changes in cervical tissue, potentially preventing progression to malignancy. While the specific mechanism of action and molecular target have not been publicly disclosed, KY1105 represents a pharmacological approach to clearing high-risk HPV infections in patients where the immune system has failed to do so.
Beyond the preview
Go deeper on KY1105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KY1105.